Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients with COVID-19: The HEP-COVID Randomized Clinical Trial

Alex C. Spyropoulos, Mark Goldin, Dimitrios Giannis, Wassim Diab, Janice Wang, Sameer Khanijo, Andrea Mignatti, Eugenia Gianos, Marc Cohen, Gulru Sharifova, Jeet M. Lund, Alfonso Tafur, Paul A. Lewis, Kevin P. Cohoon, Husneara Rahman, Cristina P. Sison, Martin L. Lesser, Kanta Ochani, Nirav Agrawal, Judith HsiaVictoria E. Anderson, Marc Bonaca, Jonathan L. Halperin, Jeffrey I. Weitz

Research output: Contribution to journalArticlepeer-review

298 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients with COVID-19: The HEP-COVID Randomized Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences